45 related articles for article (PubMed ID: 16175084)
1. Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma.
Handley KF; Mehta S; Martin AL; Biswas S; Maharaj K; Nagy MZ; Mine JA; Cortina C; Yu X; Sprenger K; Mandal G; Innamarato P; Powers JJ; Harro CM; Chaurio RA; Anadon CM; Shahzad MM; Flores I; Conejo-Garcia JR
Gynecol Oncol; 2023 Jun; 173():114-121. PubMed ID: 37121178
[TBL] [Abstract][Full Text] [Related]
2. Correlation of clinicopathological and prognostic characteristics between endometriosis-associated and primary ovarian cancer.
Wang H; Chen C; Wang D; Zhu Y; Chen P
BMC Cancer; 2023 Dec; 23(1):1210. PubMed ID: 38066448
[TBL] [Abstract][Full Text] [Related]
3. Immunologic factors involved in the malignant transformation of endometriosis to endometriosis-associated ovarian carcinoma.
Leenen S; Hermens M; de Vos van Steenwijk PJ; Bekkers RLM; van Esch EMG
Cancer Immunol Immunother; 2021 Jul; 70(7):1821-1829. PubMed ID: 33411080
[TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics and Local Histopathological Modulators of Endometriosis and Its Progression.
Istrate-Ofiţeru AM; Mogoantă CA; Zorilă GL; Roşu GC; Drăguşin RC; Berbecaru EI; Zorilă MV; Comănescu CM; Mogoantă SȘ; Vaduva CC; Brătilă E; Iliescu DG
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339066
[TBL] [Abstract][Full Text] [Related]
5. Endometriosis-Related Ovarian Cancer: Where Are We Now? A Narrative Review towards a Pragmatic Approach.
Centini G; Schettini G; Pieri E; Giorgi M; Lazzeri L; Martire FG; Mancini V; Raimondo D; Seracchioli R; Habib N; Fedele F; Zupi E
J Clin Med; 2024 Mar; 13(7):. PubMed ID: 38610698
[TBL] [Abstract][Full Text] [Related]
6. Endometriosis Stem Cells as a Possible Main Target for Carcinogenesis of Endometriosis-Associated Ovarian Cancer (EAOC).
Wilczyński JR; Szubert M; Paradowska E; Wilczyński M
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612107
[TBL] [Abstract][Full Text] [Related]
7. A Systematic Review of Atypical Endometriosis-Associated Biomarkers.
Bartiromo L; Schimberni M; Villanacci R; Mangili G; Ferrari S; Ottolina J; Salmeri N; Dolci C; Tandoi I; Candiani M
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457244
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of estrogen receptor subtypes in ovarian high-grade serous carcinoma and clear cell carcinoma.
Osaku D; Oishi T; Kawamura N; Iida Y; Komatsu H; Kudoh A; Chikumi J; Sato S; Harada T
Reprod Med Biol; 2021 Oct; 20(4):467-476. PubMed ID: 34646075
[TBL] [Abstract][Full Text] [Related]
9. Endometriosis Malignant Transformation: Epigenetics as a Probable Mechanism in Ovarian Tumorigenesis.
He J; Chang W; Feng C; Cui M; Xu T
Int J Genomics; 2018; 2018():1465348. PubMed ID: 29780815
[TBL] [Abstract][Full Text] [Related]
10. The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status.
Shafrir AL; Rice MS; Gupta M; Terry KL; Rosner BA; Tamimi RM; Hecht JL; Tworoger SS
Gynecol Oncol; 2016 Dec; 143(3):628-635. PubMed ID: 27720231
[TBL] [Abstract][Full Text] [Related]
11. Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma.
Kobayashi H; Sugimoto H; Onishi S; Nakano K
Oncol Lett; 2015 Aug; 10(2):612-618. PubMed ID: 26622542
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic determinants of ovarian clear cell carcinoma biology.
Yamaguchi K; Huang Z; Matsumura N; Mandai M; Okamoto T; Baba T; Konishi I; Berchuck A; Murphy SK
Int J Cancer; 2014 Aug; 135(3):585-97. PubMed ID: 24382740
[TBL] [Abstract][Full Text] [Related]
13. Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (Review).
Uekuri C; Shigetomi H; Ono S; Sasaki Y; Matsuura M; Kobayashi H
Oncol Lett; 2013 Nov; 6(5):1163-1173. PubMed ID: 24179489
[TBL] [Abstract][Full Text] [Related]
14. Disappearance of steroid hormone dependency during malignant transformation of ovarian clear cell cancer.
Akahane T; Sekizawa A; Okuda T; Kushima M; Saito H; Okai T
Int J Gynecol Pathol; 2005 Oct; 24(4):369-76. PubMed ID: 16175084
[TBL] [Abstract][Full Text] [Related]
15. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T
Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancers arising from endometriosis: a microenvironmental biomarker study including ER, HNF1ß, p53, PTEN, BAF250a, and COX-2.
Lai CR; Hsu CY; Chen YJ; Yen MS; Chao KC; Li AF
J Chin Med Assoc; 2013 Nov; 76(11):629-34. PubMed ID: 23962610
[TBL] [Abstract][Full Text] [Related]
17. K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma.
Otsuka J; Okuda T; Sekizawa A; Amemiya S; Saito H; Okai T; Kushima M; Tachikawa T
Med Electron Microsc; 2004 Sep; 37(3):188-92. PubMed ID: 15449112
[TBL] [Abstract][Full Text] [Related]
18. Models of endometriosis and their utility in studying progression to ovarian clear cell carcinoma.
King CM; Barbara C; Prentice A; Brenton JD; Charnock-Jones DS
J Pathol; 2016 Jan; 238(2):185-96. PubMed ID: 26456077
[TBL] [Abstract][Full Text] [Related]
19. Malignant transformation of endometriosis: application of laser microdissection for analysis of genetic alterations according to pathological changes.
Sekizawa A; Amemiya S; Otsuka J; Saito H; Farina A; Okai T; Tachikawa T
Med Electron Microsc; 2004 Jun; 37(2):97-100. PubMed ID: 15221651
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
